Answers are grounded in this paper and cite their sources.
Background: Several therapies targeting molecular alterations in subgroups of NSCLC patients (pts) have been approved and require pts to be tested for these targets. Thorough knowledge of the diagnostic and therapeutic algorithm in routine practice is crucial to evaluate and improve the quality of care.
No takes yet. Share an insight, caveat, or question.
Griesinger et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: